Elon Musk and OpenAI CEO Sam Altman began a federal civil trial this week in Oakland, California, over the origins of the AI company [1, 6].
The case represents a fundamental clash between two of the most influential figures in technology. The outcome could redefine the legal understanding of non-profit commitments in the AI sector and highlight the tension between commercial scaling and safety warnings.
Jury selection began on Monday, followed by opening arguments on Tuesday [1, 6]. Musk alleges that OpenAI misrepresented its origins and his specific role in the company's early funding [2, 5]. He said that the company shifted away from its original mission, which he believes was intended to benefit humanity rather than a small group of investors.
During the proceedings, Musk warned that the trajectory of the technology is dangerous. "AI could kill us all," Musk said [5]. He also asserted his foundational importance to the organization, stating, "Without me, OpenAI wouldn't exist" [1].
OpenAI and Altman contest these claims. An attorney for OpenAI said that the lawsuit is an attempt at "preying on Musk's humanity" [1]. The defense suggests that the dispute is less about the company's mission and more about Musk's personal grievances.
Musk also addressed his own ventures during the trial. He said that his AI company, xAI, distills models from OpenAI [5]. This admission comes as the court examines the competitive landscape of generative AI and whether OpenAI's transition to a capped-profit model violated its founding principles.
The trial continues in the U.S. federal courtroom, focusing on whether OpenAI's current structure constitutes a breach of the original agreement made with its early backers [2, 3].
“"AI could kill us all."”
This trial serves as a proxy for the broader debate over 'Effective Altruism' versus commercial acceleration in AI development. If the court finds that OpenAI violated its original non-profit mandate, it could set a legal precedent for how AI labs manage their governance structures and the obligations they owe to early donors.
